Navigation Links
Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
Date:9/16/2011

MOUNTAIN VIEW, Calif., Sept. 16, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal.  The presentations highlighted the long-term beneficial effects of QNEXA treatment in metabolically-impaired patients with prediabetes, diabetes, and metabolic syndrome.

The QNEXA presentations included:  

  • Decreased Progression to Diabetes in Subjects With Prediabetes After 2 Years of Treatment With Controlled-Release Phentermine/Topiramate, authored by W. Timothy Garvey, MD, et al.
  • Long-Term Weight Loss With Controlled-Release Phentermine/Topiramate Reverses Metabolic Syndrome and Improves Associated Traits, authored by Hermann Toplak, MD, et al.
  • Long-Term Glycaemic Effects of Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate in Overweight/Obese Subjects with Diabetes, authored by Luc F. Van Gaal, MD, et al.

  • Highlights from the EASD presentations are as follows:

    A poster presentation authored by W. Timothy Garvey, MD from the University of Alabama at Birmingham reported that patients treated over two years with QNEXA had significant reductions in the progression to type 2 diabetes and improvement in glycemic status. Of the 675 patients in the two-year SEQUEL study, 316 were determined to have prediabetes at baseline. In the prediabetic sub-group treated with QNEXA, all glycemic parameters were significantly improved at week 108 (ITT-LOCF; P<0.05 vs. placebo). Progression to diabetes was reduced in the prediabetic sub-group with top-dose QNEXA vs. placebo (P=0.0125).  

    Luc Van Gaal, MD from the University of Antwerp in Belgium and Lawrence Cheskin, MD from Johns Hopkins University Weight Management Center authored a poste
    '/>"/>

    SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. VIVUS Provides Regulatory Update on QNEXA
    2. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
    3. Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
    4. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
    5. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
    6. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
    7. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
    8. VIVUS Provides Regulatory Update on QNEXA NDA
    9. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
    10. A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity
    11. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
    (Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
    (Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
    Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
    ... Varian Medical Systems (NYSE: VAR ) ... U.S. Customs and Border Protection (CBP) for multiple IntellX® cargo ... company,s largest single order for Varian,s IntellX gantry systems. The ... vehicles for both border security and manifest verification purposes. ...
    ... 2011 DURECT Corporation (Nasdaq: DRRX ) ... (FDA) has accepted the resubmission of the New Drug ... KG ) and the PDUFA goal date ... ) REMOXY, based on DURECT,s ORADUR® technology, ...
    Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 3
    (Date:7/11/2014)... reports that tickets to the Argentina vs. Germany World ... Brazil and Netherlands are in high demand. The ... at Estadio Nacional de Brasilia Mane Garrincha Brasila, Federal District. ... 13th at Estadio Jornalista Mario Filho - Estadio do Maracana, ... are guaranteed to be authentic and are covered by Ticket ...
    (Date:7/11/2014)... 11, 2014 Butler Mobility has recently updated ... Platform Lifts . Previously the two standard colors were ... beautiful earth tone colors as standard colors at no additional ... the home but will enhance the beauty of the stairway. ... home color scheme or individual décor. , The new selection ...
    (Date:7/11/2014)... (HealthDay News) -- People with the lowest incomes may have ... disease (PAD), a new study suggests. People with PAD ... limbs, most often the legs. The condition causes leg pain ... throughout the body. People with PAD have a higher risk ... nearly 6,800 people with PAD who took part in the ...
    (Date:7/11/2014)... Volunteers from Scientology Churches ... week with drug education lectures, forums and conferences, information ... cities around the world. , Drug abuse is an ... Drug Abuse, abuse of alcohol and illicit drugs costs ... work, decreased productivity and healthcare. , In the ...
    (Date:7/11/2014)... As part of its morcellator ... has been closely monitoring the ongoing meeting of ... Obstetrics and Gynecology Devices Panel, which has been ... risks associated with the use of power morcellators ... report published by Dow Jones Business News, a ...
    Breaking Medicine News(10 mins):Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4
    ... chair to support efforts to address the rising ... in Maryland BALTIMORE, April 10 Richard H. ... General (2002-2006) and President of the non-profit Canyon ... elected Chairman of the Pharmaceutical Research and Manufacturers ...
    ... scientific article is cited by other articles is currently the ... measure: the number of unique downloads. , A recent ... that downloads are a good predictor of citations and ... in an editorial by Journal of Vision (JOV) ...
    ... 14-17, 2009, Underwriters Laboratories Inc.,s (UL) Primary Designated ... Manager Jola Wroblewska will present International Electrotechnical Committee ... (IECEE) CB Test Laboratories and National Certification Bodies ... promote common application of the guidelines prepared by ...
    ... April 10 Rheumatoid arthritis (RA) is a systemic ... defense system attacks the joints through the thin layer ... the joints. The most visible symptoms of RA are ... and feet. It can cause fatigue, fever, loss of ...
    ... eye physicians recommends , sport-specific eyewear to prevent devastating ... what started out as a routine basketball game his senior ... was a young basketball star who played years of hoops ... the eye by a teammate, Stephen ended up with a ...
    ... for skin appearance in 3 trials , , THURSDAY, April 9 ... to improve the healing of skin scars, according to three ... administered to their skin before wounding and again 24 hours ... the way through the skin of the upper inner arm ...
    Cached Medicine News:Health News:National Health Experts to Announce Creation of Bipartisan Coalition to Fight Maryland's Growing Burden of Chronic Disease Tuesday at Inner Harbor 2Health News:UL Medical Experts to Provide Instruction on Guidance for Risk Management in IEC 60601-1:2005 at IECEE Workshop 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 2Health News:Rheumatoid Arthritis Therapeutics in Taiwan 3Health News:Eye Protection is Essential for Texas Athletes 2Health News:Eye Protection is Essential for Texas Athletes 3Health News:Medication May Improve Scar Healing 2
    They employ Lea Symbols. Contrast levels are the same at 25%, 10%, 5%, 2.5% and 1.25%. Each offers a different set of Lea Symbols to guard against memorization. Also uses recording forms (P/N 215400)...
    Symbol 10' Test Chart 10/100 to 10/10 size. 9" x 14"....
    Wilbrandt-binkhorst irrigating cannula....
    Binkhorst, length 35 mm....
    Medicine Products: